Christina J. Falcon

1.6k total citations
22 papers, 304 citations indexed

About

Christina J. Falcon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Christina J. Falcon has authored 22 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Christina J. Falcon's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (8 papers) and Cancer Genomics and Diagnostics (5 papers). Christina J. Falcon is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (8 papers) and Cancer Genomics and Diagnostics (5 papers). Christina J. Falcon collaborates with scholars based in United States, Switzerland and Canada. Christina J. Falcon's co-authors include Noura J. Choudhury, Alexander Drilon, Charles M. Rudin, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Glenn Heller, Gregory J. Riely and Jessica Flynn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Christina J. Falcon

22 papers receiving 302 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina J. Falcon United States	11	215	183	98	64	23	22	304
Hanxiao Chen China	14	192 0.9×	199 1.1×	111 1.1×	64 1.0×	15 0.7×	34	388
Wouter W. Mellema Netherlands	8	207 1.0×	232 1.3×	201 2.1×	82 1.3×	17 0.7×	17	387
Sara Fancelli Italy	9	134 0.6×	197 1.1×	103 1.1×	58 0.9×	28 1.2×	25	302
Landon C. Brown United States	12	252 1.2×	195 1.1×	108 1.1×	89 1.4×	28 1.2×	29	372
Luigi Cerbone Italy	10	222 1.0×	125 0.7×	109 1.1×	93 1.5×	13 0.6×	40	308
Dina Sakaeva Russia	9	88 0.4×	165 0.9×	96 1.0×	48 0.8×	27 1.2×	44	267
Kaoru Irisa Japan	9	236 1.1×	214 1.2×	76 0.8×	48 0.8×	23 1.0×	16	333
Igor Odintsov United States	9	146 0.7×	123 0.7×	94 1.0×	52 0.8×	27 1.2×	24	235
E‐E Ke China	8	239 1.1×	200 1.1×	80 0.8×	51 0.8×	13 0.6×	12	315
Aurélie Swalduz France	11	200 0.9×	182 1.0×	126 1.3×	92 1.4×	34 1.5×	63	334

Countries citing papers authored by Christina J. Falcon

Since Specialization

Citations

This map shows the geographic impact of Christina J. Falcon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina J. Falcon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina J. Falcon more than expected).

Fields of papers citing papers by Christina J. Falcon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina J. Falcon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina J. Falcon. The network helps show where Christina J. Falcon may publish in the future.

Co-authorship network of co-authors of Christina J. Falcon

This figure shows the co-authorship network connecting the top 25 collaborators of Christina J. Falcon. A scholar is included among the top collaborators of Christina J. Falcon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina J. Falcon. Christina J. Falcon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Middha, Pooja, Rohit Thummalapalli, Zoe Quandt, et al.. (2025). Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. Journal for ImmunoTherapy of Cancer. 13(3). e011273–e011273. 1 indexed citations

Harada, Guilherme, Fernando C. Santini, Jason C. Chang, et al.. (2025). Final results of a phase II study of cabozantinib in patients with MET -altered lung cancers.. Journal of Clinical Oncology. 43(16_suppl). 8645–8645. 1 indexed citations

Thummalapalli, Rohit, Christopher A. Febres‐Aldana, Christina J. Falcon, et al.. (2024). Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8599–8599. 1 indexed citations

Chen, Monica F., Àlvaro Quintanal-Villalonga, Jake J. Lee, et al.. (2024). Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.. Journal of Clinical Oncology. 42(16_suppl). 8565–8565. 5 indexed citations

Murciano‐Goroff, Yonina R., Christina J. Falcon, Sabrina T. Lin, et al.. (2023). Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. Journal of Thoracic Oncology. 18(5). 620–627. 12 indexed citations

Chen, Monica F., Guilherme Harada, Dazhi Liu, et al.. (2023). Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function. Journal of Thoracic Oncology. 19(1). 153–159. 11 indexed citations

Bowman, Alan S., Christina J. Falcon, Romel Somwar, et al.. (2023). P2.09-14 Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations. Journal of Thoracic Oncology. 18(11). S337–S337. 1 indexed citations

Solomon, James P., Soo‐Ryum Yang, Noura J. Choudhury, et al.. (2022). Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. Clinical Cancer Research. 28(21). 4649–4659. 12 indexed citations

Ali, Moiez, Min Lu, Ryan S. Soderquist, et al.. (2022). Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine. 14(638). eabc7480–eabc7480. 29 indexed citations

10.

Choudhury, Noura J., Antonio Marra, Jessica Flynn, et al.. (2022). Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology. 18(4). 463–475. 58 indexed citations

11.

Selenica, Pier, Antonio Marra, Noura J. Choudhury, et al.. (2022). APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals of Oncology. 33(12). 1284–1295. 23 indexed citations

12.

Kalchiem‐Dekel, Or, Christina J. Falcon, Christine M. Bestvina, et al.. (2022). Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology. 17(9). 1130–1136. 29 indexed citations

13.

Harada, Guilherme, Noura J. Choudhury, Alison M. Schram, et al.. (2022). Mechanisms of acquired resistance to TRK inhibitors.. Journal of Clinical Oncology. 40(16_suppl). 3104–3104. 11 indexed citations

14.

Hubbeling, Harper, Noura J. Choudhury, Jessica Flynn, et al.. (2022). Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers. JCO Precision Oncology. 6(6). e2200024–e2200024. 7 indexed citations

15.

Kalchiem‐Dekel, Or, Christina J. Falcon, Christine M. Bestvina, et al.. (2022). Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.. Journal of Clinical Oncology. 40(16_suppl). 9080–9080. 2 indexed citations

16.

Harada, Guilherme, Christina J. Falcon, Fernando C. Santini, et al.. (2022). Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization. Cancer Research. 82(12_Supplement). 868–868. 1 indexed citations

17.

Choudhury, Noura J., Adam J. Schoenfeld, Jessica Flynn, et al.. (2021). Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research. 27(10). 2920–2927. 47 indexed citations

18.

Hubbeling, Harper, Noura J. Choudhury, Christina J. Falcon, et al.. (2021). Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers. International Journal of Radiation Oncology*Biology*Physics. 111(3). e438–e439. 4 indexed citations

19.

Choudhury, Noura J., Jaime L. Schneider, Tejas Patil, et al.. (2021). Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports. 2(7). 100187–100187. 26 indexed citations

20.

Offin, Michael, Jia Luo, Robin Guo, et al.. (2020). CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib. JCO Precision Oncology. 4(4). 871–876. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact